Black Diamond Therapeutics Ownership | Who Owns Black Diamond Therapeutics?

Black Diamond Therapeutics Ownership Summary

Black Diamond Therapeutics is owned by 67.25% institutional investors, 0.62% insiders, and 32.13% retail investors. T. rowe price investment management is the largest institutional shareholder, holding 18.50% of BDTX shares. BB Biotech AG Ord is the top mutual fund, with 15.05% of its assets in Black Diamond Therapeutics shares.

BDTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Black Diamond Therapeutics	67.25%	0.62%	32.13%
Sector	Healthcare Stocks	35.71%	11.88%	52.42%
Industry	Biotech Stocks	35.98%	11.86%	52.17%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
T. rowe price investment management	10.56M	18.50%	$22.50M
Nea management company	4.45M	7.79%	$9.48M
Blackrock	3.22M	6.21%	$14.99M
Acadian asset management	2.35M	4.11%	$5.00M
Vanguard group	2.19M	3.86%	$5.32M
Tang capital management	2.07M	3.64%	$7.85M
Renaissance	1.64M	2.88%	$3.50M
Dimensional fund advisors lp	1.30M	2.28%	$2.77M
Artal group	1.05M	2.02%	$4.88M
Blackrock funding, inc. /de	1.11M	1.94%	$2.36M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Nea management company	4.45M	0.54%	$9.48M
Tang capital management	2.07M	0.30%	$7.85M
Dafna capital management	307.07K	0.29%	$1.16M
Artal group	1.05M	0.12%	$4.88M
Boxer capital	506.00K	0.12%	$2.36M
Awm investment company	525.00K	0.12%	$1.12M
Globeflex capital l p	305.28K	0.10%	$650.24K
Round rock advisors	274.37K	0.09%	$584.40K
Nverses capital	31.41K	0.06%	$66.91K
Winton group	538.26K	0.04%	$1.15M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	3.22M	0.00%	1.84M
Acadian asset management	2.35M	0.01%	718.48K
Renaissance	1.64M	0.01%	694.01K
Bridgeway capital management	723.48K	0.03%	550.18K
Balyasny asset management	510.81K	0.00%	510.81K

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-3.53M
Bellevue group	-	-	-2.73M
Siren	-	-	-1.05M
Laurion capital management lp	-	-	-878.29K
Exoduspoint capital management, lp	-	-	-872.68K

New Positions

Holder	Shares	% Assets	Change	Value
Balyasny asset management	510.81K	0.00%	510.81K	$1.09M
Vanguard fiduciary trust	259.91K	0.00%	259.91K	$553.60K
Empowered funds	230.18K	0.00%	230.18K	$490.28K
Bailard	51.50K	0.00%	51.50K	$109.69K
Two sigma investments, lp	43.30K	0.00%	43.30K	$92.23K

Sold Out

Holder	Change
Mid-american wealth advisory group	-19.00
Geowealth management	-26.00
Northwestern mutual wealth management	-35.00
Caitong asset management	-74.00
Lindbrook capital	-83.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	106	-3.64%	38,394,284	1.42%	67	1.51%	53	-14.52%	32	18.52%
Dec 31, 2025	21	-76.67%	3,275,099	-91.55%	5	0.12%	10	-79.59%	6	-73.91%
Sep 30, 2025	23	-75.00%	2,937,554	-92.39%	5	0.11%	10	-84.13%	5	-68.75%
Jun 30, 2025	92	4.55%	38,616,348	-5.24%	67	1.31%	63	90.91%	17	-43.33%
Mar 31, 2025	88	-1.12%	40,752,553	-14.93%	71	1.00%	32	-39.62%	31	82.35%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
BB Biotech AG Ord	8.52M	15.05%	-
T. Rowe Price Small-Cap Stock	2.65M	4.62%	-
T. Rowe Price US Small-Cap Core Equity	2.65M	4.62%	-4.00K
T. Rowe Price Small-Cap Value	2.13M	3.72%	-
T. Rowe Price Instl Small-Cap Stock	1.40M	2.44%	-
T. Rowe Price U.S. SC Value Eq Tr-D	1.36M	2.38%	2.92K
Vanguard US Total Market Shares ETF	1.33M	2.35%	-
Vanguard Total Stock Mkt Idx Inv	1.30M	2.26%	-
T. Rowe Price U.S. SC Core Eq Tr-D	1.29M	2.25%	4.00K
T. Rowe Price U.S. SC Value Eq Tr-Z	1.24M	2.19%	2.28K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$4.00M
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$2.31M
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$582.90K
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$2.07M
Mar 19, 2025	BIOTECH GROWTH N V	-	Sell	$837.16K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q4	-	-
2025 Q3	-	-
2025 Q2	-	-
2025 Q1	-	7

BDTX Ownership FAQ

Who Owns Black Diamond Therapeutics?

Black Diamond Therapeutics shareholders are primarily institutional investors at 67.25%, followed by 0.62% insiders and 32.13% retail investors. The average institutional ownership in Black Diamond Therapeutics's industry, Biotech Stocks , is 35.98%, which Black Diamond Therapeutics exceeds.

Who owns the most shares of Black Diamond Therapeutics?

Black Diamond Therapeutics’s largest shareholders are T. rowe price investment management (10.56M shares, 18.50%), Nea management company (4.45M shares, 7.79%), and Blackrock (3.22M shares, 6.21%). Together, they hold 32.50% of Black Diamond Therapeutics’s total shares outstanding.

Does Blackrock own Black Diamond Therapeutics?

Yes, BlackRock owns 6.21% of Black Diamond Therapeutics, totaling 3.22M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 14.99M$. In the last quarter, BlackRock increased its holdings by 1.84M shares, a 133.04% change.

Who is Black Diamond Therapeutics’s biggest shareholder by percentage of total assets invested?

Nea management company is Black Diamond Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.54% of its assets in 4.45M Black Diamond Therapeutics shares, valued at 9.48M$.

Who is the top mutual fund holder of Black Diamond Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Black Diamond Therapeutics shares, with 15.05% of its total shares outstanding invested in 8.52M Black Diamond Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools